Literature DB >> 16515485

Current HIV treatment guidelines--an overview.

R C Rathbun1, S M Lockhart, J R Stephens.   

Abstract

Use of highly active antiretroviral therapy has resulted in significant reductions in HIV-related morbidity and mortality. Current therapeutic approaches target cellular entry, viral transcription, and maturation of newly formed virus. Combination therapy is necessary to provide durable suppression of viral replication and immune reconstitution. A variety of consensus treatment guidelines addressing prophylaxis and treatment of HIV infection and opportunistic infections have been developed to serve as resources for clinicians. A summary of U.S. Department of Health and Human Services Guidelines for Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents and International AIDS Society-USA Panel recommendations for Treatment of Adult HIV infection are presented. Considerations for selection of antiretroviral therapy in special populations (e.g., pregnancy, coinfection with tuberculosis, hepatitis B and C virus) are highlighted. U.S. Public Health Service guidelines for management of occupational exposure to HIV and initiation of postexposure prophylaxis are discussed as well as World Health Organization recommendations for use of antiretroviral therapy in resource-limited settings. The pathophysiology of HIV infection, viral load testing methods, viral dynamics, and classification of antiretrovirals are also briefly reviewed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16515485     DOI: 10.2174/138161206776055840

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  22 in total

1.  Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS/MS.

Authors:  Nagsen Gautam; Zhiyi Lin; Mary G Banoub; Nathan A Smith; Audai Maayah; JoEllyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  J Pharm Biomed Anal       Date:  2018-02-20       Impact factor: 3.935

Review 2.  Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.

Authors:  Youry Kim; Jenny L Anderson; Sharon R Lewin
Journal:  Cell Host Microbe       Date:  2018-01-10       Impact factor: 21.023

3.  A systematic review of best practices in HIV care.

Authors:  Geoffrey Maina; Judy Mill; Jean Chaw-Kant; Vera Caine
Journal:  J HIV AIDS Soc Serv       Date:  2016-03-22

4.  Barriers to kidney transplant evaluation in HIV-positive patients with advanced kidney disease: A single-center study.

Authors:  Suzanne M Boyle; Kallie Fehr; Catylin Deering; Abbas Raza; Meera N Harhay; Gregory Malat; Karthik Ranganna; Dong Heun Lee
Journal:  Transpl Infect Dis       Date:  2020-02-12       Impact factor: 2.228

5.  Crystal structure of an engineered, HIV-specific recombinase for removal of integrated proviral DNA.

Authors:  Gretchen Meinke; Janet Karpinski; Frank Buchholz; Andrew Bohm
Journal:  Nucleic Acids Res       Date:  2017-09-19       Impact factor: 16.971

6.  Triple positivity of HBsAg, anti-HCV antibody, and HIV and their influence on CD4+ lymphocyte levels in the highly HIV infected population of Abeokuta, Nigeria.

Authors:  Sandra Olukemi Ogwu-Richard; David Ajiboye Ojo; Olusola Abiodun Akingbade; Iheanyi Omezuruike Okonko
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

7.  Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Authors:  Amanda B Macedo; Camille L Novis; Caroline M De Assis; Eric S Sorensen; Paula Moszczynski; Szu-Han Huang; Yanqin Ren; Adam M Spivak; R Brad Jones; Vicente Planelles; Alberto Bosque
Journal:  JCI Insight       Date:  2018-10-04

8.  Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.

Authors:  Nagsen Gautam; Upal Roy; Shantanu Balkundi; Pavan Puligujja; Dongwei Guo; Nathan Smith; Xin-Ming Liu; Benjamin Lamberty; Brenda Morsey; Howard S Fox; Joellyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

9.  Seroprevalence of HBV and HIV co-infection in children and outcomes following highly active antiretroviral therapy (HAART) in Uyo, South-South Nigeria.

Authors:  E E Ikpeme; O M Etukudo; U E Ekrikpo
Journal:  Afr Health Sci       Date:  2013-12       Impact factor: 0.927

10.  Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.

Authors:  Nagsen Gautam; Pavan Puligujja; Shantanu Balkundi; Rhishikesh Thakare; Xin-Ming Liu; Howard S Fox; JoEllyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.